Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/171256Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.creator | Tonin, FS | |
| dc.creator | Tsuyuki, RT | |
| dc.creator | Fernandez-Llimos, F | |
| dc.creator | Garcia-Cardenas, V | |
| dc.creator | Laufs, U | |
| dc.creator | Schulz, M | |
| dc.date.accessioned | 2025-12-09T00:05:53Z | - |
| dc.date.available | 2025-12-09T00:05:53Z | - |
| dc.date.issued | 2025 | |
| dc.identifier.issn | 1715-1635 | |
| dc.identifier.other | sigarra:737514 | |
| dc.identifier.uri | https://hdl.handle.net/10216/171256 | - |
| dc.description.abstract | Background: Pharmacist-led interventions have demonstrated benefits across various medical conditions; however, their impact on atrial fibrillation (AF) remains unexplored. This study aims to synthesize the available evidence regarding the pharmacist's role in AF management.Methods: A systematic review with searches in PubMed, Scopus, and Web of Science was performed (PROSPERO: CRD42025647848). Randomized and non-randomized trials, as well as cohort studies reporting clinical, process, and humanistic outcomes, were included. Findings were pooled through pairwise meta-analyses. Dichotomous outcomes were reported as risk ratios (RRs) and continuous variables as standardized mean differences (SMDs) with 95% confidence intervals (CIs). The quality of the randomized and non-randomized studies was assessed using RoB 2.0 and ROBINS-I tools, respectively. Evidence was graded using the GRADE approach.Results: Seventeen studies (n = 11,428 participants) published between 2008 and 2024, predominantly as non-randomized trials/cohorts (77%), were included. Pharmacist-led interventions varied widely in scope, including anticoagulation management services, medication therapy management, and prescribing. Meta-analyses showed that pharmacists improved time in therapeutic range (SMD 0.35; 95% CI, 0.13-0.56) and reduced major bleeding events (RR 0.76; 95% CI, 0.61-0.95) and strokes (RR 0.65; 95% CI, 0.44-0.94) compared with usual care. Pharmacist care also increased appropriate prescription rates (RR 1.36, 95% CI, 1.18-1.56). No significant differences were found for other outcomes. Evidence was of low-to-moderate certainty.Interpretation: Pharmacist-led interventions have been shown to improve certain clinical and process outcomes in AF.Conclusions: High-quality randomized studies with well-defined interventions are still needed to better refine the pharmacist's role in AF care and to identify the most effective intervention in practice (see Graphical Abstract). Can Pharm J (Ott) 2025;158:xx-xx. | |
| dc.language.iso | eng | |
| dc.rights | openAccess | |
| dc.title | The role of pharmacists in the management of patients with atrial fibrillation: A systematic review and meta-analysis | |
| dc.type | Artigo em Revista Científica Internacional | |
| dc.contributor.uporto | Faculdade de Farmácia | |
| dc.identifier.doi | 10.1177/17151635251365148 | |
| dc.identifier.authenticus | P-019-YSV | |
| Appears in Collections: | FFUP - Artigo em Revista Científica Internacional | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| 737514.pdf | 3.58 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
